Acerus Pharmaceuticals Corporation announced the Health Canada approval of NATESTO™, the first and only nasal gel for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). NATESTO™ is the lowest dose testosterone gel replacement therapy to be approved in Canada, with the majority of men achieving normal testosterone levels in a Phase III study. In addition, NATESTO™ demonstrated significant improvements in erectile function, intercourse satisfaction, orgasmic function, sexual desire, overall satisfaction and positive mood versus baseline.

The product utilizes a bioadhesive nasal gel technology, allowing for convenient, ‘no-touch' administration within seconds, rapid absorption and reduced risk of secondary transference to women and children. NATESTO™ has a recommended twice-daily starting dose, which can be adjusted up to a three times daily dose if needed. NATESTO™ is expected to be commercially available in Canada by mid-2016.